Feb 17 (Reuters) - Sigma Pharmaceuticals Ltd SIP.AX :
* Advise that underlying ebit is expected to be just over $100 million for fy
* Fy reported ebit is however expected to be broadly in line with last year
* Sigma pharmaceuticals ltd - "remain comfortable with our existing guidance of at least 5% underlying ebit growth for 2017/18 financial year"
* Sigma pharmaceuticals - new guidance for full year compares with previous guidance of 10% underlying ebit growth Source text for Eikon: ID:nASX9dNYxr Further company coverage: SIP.AX